JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

Search

Alkermes PLC

Aperta

SettoreSettore sanitario

30.21 -3.3

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.88

Massimo

31.32

Metriche Chiave

By Trading Economics

Entrata

65M

87M

Vendite

84M

391M

P/E

Media del settore

14.613

37.461

Margine di Profitto

22.295

Dipendenti

1,800

EBITDA

99M

113M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+29.09% upside

Dividendi

By Dow Jones

Utili prossimi

28 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

802M

5.1B

Apertura precedente

33.51

Chiusura precedente

30.21

Notizie sul Sentiment di mercato

By Acuity

50%

50%

168 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Alkermes PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 ott 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 ott 2025, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 ott 2025, 21:20 UTC

Utili

Correction to IBM 3Q Sales Jump Article

22 ott 2025, 20:57 UTC

Utili

SAP Posts Higher 3Q Revenue, Operating Profit

22 ott 2025, 23:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 ott 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 ott 2025, 23:41 UTC

Discorsi di Mercato

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 ott 2025, 23:38 UTC

Discorsi di Mercato

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 ott 2025, 23:15 UTC

Utili

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 ott 2025, 22:28 UTC

Discorsi di Mercato

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 ott 2025, 22:02 UTC

Utili

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 ott 2025, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 ott 2025, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 ott 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 ott 2025, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 ott 2025, 21:47 UTC

Acquisizioni, Fusioni, Takeovers

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 ott 2025, 21:47 UTC

Utili

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 ott 2025, 21:47 UTC

Acquisizioni, Fusioni, Takeovers

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 ott 2025, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 ott 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 ott 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 ott 2025, 21:28 UTC

Discorsi di Mercato
Utili

Correction to Alcoa Tariff Market Talk

22 ott 2025, 21:25 UTC

Utili

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 ott 2025, 21:17 UTC

Utili

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 ott 2025, 21:09 UTC

Discorsi di Mercato
Utili

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 ott 2025, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

22 ott 2025, 20:59 UTC

Utili

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 ott 2025, 20:51 UTC

Utili

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 ott 2025, 20:44 UTC

Utili

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Confronto tra pari

Modifica del prezzo

Alkermes PLC Previsione

Obiettivo di Prezzo

By TipRanks

29.09% in crescita

Previsioni per 12 mesi

Media 40.6 USD  29.09%

Alto 47 USD

Basso 33 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alkermes PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

27.95 / 30.91Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

168 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat